Q3 2025 Alkermes Plc Earnings Call Transcript
Key Points
- Alkermes PLC (ALKS) reported strong third-quarter financial results with total revenues of $394.2 million, driven by a 16% year-over-year growth in net sales of proprietary products.
- The company raised its full-year 2025 financial guidance, reflecting confidence in its business momentum and strong commercial execution.
- The proposed acquisition of Avadel Pharmaceuticals is expected to diversify Alkermes' commercial portfolio and strengthen profitability with the addition of LUMRYZ, an FDA-approved medicine with significant growth potential.
- Alkermes' orexin 2 receptor agonist, alixorexton, showed positive Phase 2 data for narcolepsy type 1, and the company plans to initiate a global Phase 3 program early next year.
- The company maintains a strong financial position with $1.14 billion in cash and total investments, supporting its strategic priorities and growth trajectory.
- Research and development expenses increased to $81.7 million from $59.9 million in the previous year, reflecting higher investments in clinical studies.
- Selling, general, and administrative expenses rose to $171.8 million from $150.4 million, partly due to the expansion of the psychiatry field organization and promotional activities.
- The acquisition of Avadel Pharmaceuticals will require financing through cash and bank debt, which may impact the company's financial flexibility.
- There is uncertainty regarding the gross-to-net adjustments for products like LYBALVI, which could affect future financial performance.
- The company faces competitive challenges in the psychiatric and sleep medicine markets, requiring continued investment in sales and marketing efforts.
Greetings, and welcome to the Alkermes third quarter 2025 financial results conference call. My name is Rob and I'll be your operator for today's call.
(Operator Instructions) Please note that this conference is being recorded. I will now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs.
Sandy, you may now begin.
Thanks, Rob. Welcome to the Alkermes Plc conference call to discuss our financial results and business update for the quarter ended September 30, 2025. With me today are Richard Pops, our CEO; Blair Jackson, our Chief Operating Officer; Todd Nichols, our Chief Commercial Officer; and Joshua Reed, our Chief Financial Officer.
A slide presentation along with our press release, related financial tables, and reconciliations of the GAAP to non-GAAP financial measures that we'll discuss today are available on the investor section of alkermes.com. We believe the non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
